Rubicon Research (RUBICON) Stock Overview

Operates as a specialty pharmaceutical company in India, the United States, and internationally. More details

RUBICON fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	6/6
Past Performance	5/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings are forecast to grow 33.03% per year

Earnings grew by 52.1% over the past year

Risk Analysis

High level of non-cash earnings

Has a high level of debt

RUBICON Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Rubicon Research Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rubicon Research
Historical stock prices
Current Share Price	₹636.50
52 Week High	₹754.80
52 Week Low	₹570.75
Beta	0
1 Month Change	-10.83%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.32%

Recent updates

Shareholder Returns

	RUBICON	IN Pharmaceuticals	IN Market
7D	3.5%	-0.4%	-0.3%
1Y	n/a	-2.2%	-2.3%

Return vs Industry: Insufficient data to determine how RUBICON performed against the Indian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how RUBICON performed against the Indian Market.

Price Volatility

Is RUBICON's price volatile compared to industry and market?
RUBICON volatility
RUBICON Average Weekly Movement	6.3%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	5.2%
10% most volatile stocks in IN Market	8.6%
10% least volatile stocks in IN Market	3.1%

Stable Share Price: RUBICON has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine RUBICON's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	903	Parag Sancheti	www.rubicon.co.in

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant.

Rubicon Research Limited Fundamentals Summary

How do Rubicon Research's earnings and revenue compare to its market cap?
RUBICON fundamental statistics
Market cap	₹104.86b
Earnings (TTM)	₹1.71b
Revenue (TTM)	₹14.36b

61.2x

P/E Ratio

7.3x

P/S Ratio

Is RUBICON overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RUBICON income statement (TTM)
Revenue	₹14.36b
Cost of Revenue	₹4.54b
Gross Profit	₹9.82b
Other Expenses	₹8.11b
Earnings	₹1.71b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	10.41
Gross Margin	68.40%
Net Profit Margin	11.94%
Debt/Equity Ratio	79.8%

How did RUBICON perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/15 18:04
End of Day Share Price	2025/12/15 00:00
Earnings	2025/09/30
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rubicon Research Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Motilal Oswal Securities Ltd.
Tushar Manudhane	Motilal Oswal Securities Ltd.

Rubicon Research LimitedNSEI:RUBICON Stock Report